FDA wants more info before approving Merck's chronic cough drug

Pharmaceutical company Merck has revealed that gefapixant, its experimental drug designed to address chronic cough, still has a ways to go before hitting the US market. As part of its announcement, Merck said it has received a Complete Response Letter (CRL) from the FDA seeking more details about the drug’s efficacy, meaning the agency has declined to approve the treatment …